קיורוסורף
abic marketing ltd, israel - phospholipids fraction from porcine lung - תרחיף - phospholipids fraction from porcine lung 80 mg/ml - lung surfactants - treatment of preterm babies with respiratory distress syndrome (rds). prophylactic use in premature infants at high risk of rds.
אינפסורף
rafa laboratories ltd - calfactant as phospholipid - תרחיף - calfactant as phospholipid 35 mg/ml - lung surfactants - infasurf is indicated for the prevention of respiratory distress syndrome (rds) in premature infants at high risk for rds and for the treatment ("rescue") of premature infants who develop rds. infasurf decreases the incidence of rds mortality due to rds and air leaks associated with rds. prophylaxis : prophylaxis therapy at birth with infasurf is indicated for premature infants <29 weeks of gestational age at significant risk for rds. infasurf prophylaxis should be administered as soon as possible preferably within 30 minutes after birth. treatment: infasurf therapy is indicated for infants 72 hours of age with rds (confirmed by clinical and radiologic findings) and requiring endotracheal intubation.
רנוולה טבליות 800 מג
sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
רנוולה אבקה 2.4 גרם
sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
וולפורו
cts ltd - iron as sucroferric oxyhydroxide - טבליות לעיסות - iron as sucroferric oxyhydroxide 500 mg - sucroferric oxyhydroxide
אומניטרופ 10 מג \1.5 מל
novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 10 mg / 1.5 ml - somatropin
אומניטרופ 15 מג \1.5 מל
novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 15 mg / 1.5 ml - somatropin
אומניטרופ 5 מג \1.5 מל
masrouji co, ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 5 mg / 1.5 ml - somatropin
אלוקום קרם
organon pharma israel ltd., israel - mometasone furoate - קרם - mometasone furoate 0.1 % - mometasone - mometasone - for the relief of the inflammatory and pruritic manifestation of corticisteroid responsive dermatoses